— Know what they know.
Not Investment Advice

FATE NASDAQ

Fate Therapeutics, Inc.
1W: +10.5% 1M: +53.3% 3M: +43.8% YTD: +87.5% 1Y: +127.2% 3Y: -62.8% 5Y: -97.3%
$2.25
+0.15 (+7.14%)
 
Weekly Expected Move ±23.6%
$1 $1 $2 $2 $3
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 59 · $262.3M mcap · 102M float · 2.16% daily turnover · Short 38% of daily vol

Balance Sheet Trends

Total Assets
$319M -27.6% ▼
5Y CAGR: -12.5%
Total Liabilities
$112M -8.4% ▼
5Y CAGR: -14.0%
Shareholders Equity
$207M -35.0% ▼
5Y CAGR: -11.6%
Cash & Investments
$204M -27.0% ▼
5Y CAGR: -15.9%
Total Debt
$78M -8.7% ▼
5Y CAGR: -4.4%
Net Debt
$31M -36.6% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$134M$61M$42M$36M$47M
Short-Term Investments$482M$375M$273M$243M$157M
Cash & ST Investments$616M$436M$315M$279M$204M
Net Receivables$9M$38M$2M$4M$916K
Inventory$0$0$0$0$0
Other Current Assets$0$27M$900K$9M$4M
Total Current Assets$633M$502M$332M$292M$209M
Property, Plant & Equip.$162M$66M$159M$111M$99M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$101M$5M$980K$28M$1M
Other Non-Current Assets$25M$132M$15M$10M$10M
Total Non-Current Assets$288M$203M$175M$149M$110M
Total Assets$921M$706M$506M$441M$319M
— Liabilities —
Accounts Payable$9M$8M$5M$9M$3M
Short-Term Debt$0$0$0$0$5M
Deferred Revenue$21M$42M$0$393K$381K
Other Current Liabilities$3M$40M$685K$12M$28M
Total Current Liabilities$81M$114M$39M$39M$36M
Long-Term Debt$0$0$0$0$73M
Other Non-Current Liab.$25M$4M$1M$6M$2M
Total Non-Current Liabilities$161M$108M$99M$83M$76M
Total Liabilities$243M$222M$138M$122M$112M
— Equity —
Common Stock$96K$97K$99K$114K$115K
Retained Earnings-$769M-$1.1B-$1.2B-$1.4B-$1.5B
Accumulated OCI-$762K-$2M$15K$268K$116K
Total Stockholders Equity$679M$484M$368M$319M$207M
Total Liabilities & Equity$921M$706M$506M$441M$319M
— Key Metrics —
Total Debt$115M$109M$104M$85M$78M
Net Debt-$19M$48M$62M$49M$31M
Total Investments$583M$380M$274M$271M$159M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms